The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because psychedelics are not only beneficial in populations suffering from psychopathologies, but also for those without, enhancing social and cognitive skills such as empathy and creativity, but also general well-being (18, 112).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These associations could reflect target engagement (ketamine-induced glutamate release), leading to dissociative effects, a subsequent elicitation of synaptogenesis and resultant antidepressant response 28,56,57 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the dose-response relationship between the glutamate surge, synaptogenesis and antidepressant response following ketamine administration 28,56,57 , it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Cited by
Items 201–300 of 541
Schenberg, E. E. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70097 · Cited by 16
“…are indispensable for different disorders, and the interactions among them are still open for further research, but the appreciation of a complex causal model depends on differing philosophical commitments regarding the experiential domain and lived experiences in psychedelic research [113, 114].”
The fundamental tension in integrated information theory 4.0’s realist idealism
Cea, I., Negro, N., & Signorelli, C. M. (2023) · Entropy · doi:10.3390/e25101453 · Cited by 13
“…of the causal difference that consciousness seems to make in a diversity of phenomena such as motivation [52–56], psychedelic medicine [57–60], information integration and behavioural flexibility [61], free will [62–65], and other psychological and behavioural functions [66–69], thus…”
BackgroundBarnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
“26 According to this view, 22 the spe-cific qualities of the acute subjective effects, context, salience, and significance of the experience itself are of paramount importance, and that various self-report constructs may help to clarify the persisting therapeutic mechanisms of psychedelics.”
Jastrzębski, M. K., Wójcik, P., Grudzińska, A., Andreozzi, G., Vetrò, T., Asim, A., Mudgal, A., Czapiński, J., Wróbel, T. M., Bartuzi, D., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.002 · Cited by 15
“The literature seems to be not conclusive in this regard 109 — 111 .”
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Chambers, R., Stoliker, D., & Simonsson, O. (2023) · Mindfulness · doi:10.1007/s12671-023-02206-4 · Cited by 16
“Intriguingly, this dissolution of self-boundaries has been linked to potential therapeutic benefits and suggests that therapeutic outcomes may depend upon the psychological quality of the psychedelic experience (Roseman et al., 2018; Yaden & Griffiths, 2020).”
Spirituality as a Therapeutic Approach for Severe Mental Illness: Insights from Neural Networks
Knegtering, H., Bruggeman, R., & Spoelstra, S. K. (2024) · Religions · doi:10.3390/rel15040489 · Cited by 25
Atiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 18
“The purpose of this review stems from recent debates about the necessity of ASE for sustained clinical benefits of classic psychedelics (Majic et al. 2015; Nautiyal & Yaden 2023; Olson 2021; Yaden & Griffiths 2021).”
InfluentialNicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 19
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Halman, A., Conyers, R. K., Moore, C., Khatri, D., Sarris, J. J., & Perkins, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3459 · Cited by 19
“11,12 It is suggested that the acute subjective effects of psychedel-ics, the intensity of which typically correlate with doses, 13–15 are required for their therapeutic effects, 16 or at least necessary for achieving maximal efficacy.”
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
“This study agrees with Yaden and Griffiths [116] saying that some subjective effects occasioned by moderate to high doses of psychedelics in humans are necessary for their full and enduring therapeutic effects.”
Meccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
“However, human clinical work continues to emphasize a potential link between the acute mystical and spiritually transformative aspects of psychedelics and the enduring changes in mood (Barrett and Griffiths 2018; Roseman et al. 2018; Yaden and Griffiths 2021).”
BackgroundYaden, D. B., Berghella, A. P., Hendricks, P. S., Yaden, M. E., Levine, M., Rohde, J. S., Nayak, S. M., Johnson, M. W., & Garcia‐Romeu, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106998 · Cited by 14
Self-citationHuman behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
“Although in the case of depression the magnitude of the subjective experience is reported to correlate with clinical outcome, the causal link with the therapeutic effect is not proven and much discussed in recent commentaries (Olson, 2021; Yaden & Griffiths, 2021).”
On Redescribing the Indescribable: Trauma, Psychoanalysis and Psychedelic Therapy
Modlin, N. L., Stubley, J., Maggio, C., & Rucker, J. (2023) · British Journal of Psychotherapy · doi:10.1111/bjp.12852 · Cited by 15
Acute Subjective Effects of Psychedelics within and Beyond WEIRD Contexts
Graziosi, M., Singh, M., Nayak, S. M., & Yaden, D. B. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2255274 · Cited by 15
“The attention on the subjective effects is important given that these effects are correlated with the therapeutic response, especially enduring beneficial effects (Nautiyal and Yaden 2023; Yaden and Griffiths 2020).”
BackgroundSelf-citationPsychedelics as a potential treatment for tobacco use disorder: a systematic review
Spoelstra, S. K., Schoevers, R. A., Venema, S. D., & Knegtering, H. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00095-0 · Cited by 14
“Although some researchers believe that psychedelic experiences while using psychedelics predict therapeutic effects in managing addiction, others tend to regard these experiences just as an unnecessary side-effect [23, 25–27].”
BackgroundThe serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Fleury, S., & Nautiyal, K. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03387-1 · Cited by 16
Mystical experiences without mysticism: An argument for mystical fictionalism in psychedelics
Armour‐Garb, B., & Earleywine, M. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00207 · Cited by 19
Deep CANALs: a deep learning approach to refining the canalization theory of psychopathology
Juliani, A., Safron, A., & Kanai, R. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae005 · Cited by 15
“However, this is complicated by the fact that the specific mental circuits involved during the acute and postacute effects of psychedelic therapy appear to be essential for meaningful positive outcomes (Yaden and Griffiths, 2020).”
The Promise of Psychedelic Science
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 14
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · doi:10.1101/2021.02.24.432725 · Cited by 11
Altered States of Consciousness During Ceremonial San Pedro Use
Bohn, A., Kiggen, M. H. H., Uthaug, M. V., van Oorsouw, K. I. M., Ramaekers, J. G., & van Schie, H. T. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2139502 · Cited by 12
“The main scale investigates the occurrence of a mystical-type experience, an important predictor that is hypothesized to be one of the responsible mechanisms for the clinical outcomes of psychedelics (Yaden & Griffiths, 2020).”
BackgroundLeveraging the Metaverse for Enhanced Longevity as a Component of Health 4.0
Pillay, S. S., Candela, P., Croghan, I. T., Hurt, R. T., Bonnes, S. L. R., Ganesh, R., & Bauer, B. A. (2024) · Mayo Clinic Proceedings Digital Health · doi:10.1016/j.mcpdig.2024.01.007 · Cited by 13
Echeverry, C., Pazos, M., Torres‐Pérez, M., & Prunell, G. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.039 · Cited by 14
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
“Furthermore, the occurrence of mystical experience seems to be a predictable marker of successive treat-ment in depressed individuals [129].”
BackgroundThe Epidemiology of Psychedelic Use Among United States Military Veterans
Davis, A. K., Bates, M. J., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., Koffman, R. L., Hooyer, K., & Yehuda, R. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2401977 · Cited by 12
“…of acceptance and surrender are predictive of a more positive, less challenging, psychedelic experience (Aday et al. 2021) and of more mystical-type experiences (Haijen et al. 2018), which have been correlated with positive therapeutic outcomes across clinical trials (Yaden and Griffiths 2020).”
Petridis, P. D., Grinband, J., Agin-Liebes, G., Kinslow, C. J., Zeifman, R. J., Bogenschutz, M. P., Griffiths, R. R., & Ross, S. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00331-0 · Cited by 11
“The effects of psilocybin may also be attributable to the profound psycho-spiritual experiences that are commonly occasioned during dosing sessions 21,48 .”
Self-citationYaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R. L., Ching, T. H. W., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0019 · Cited by 13
“5,6 7 – 10 Some psychedelics were synthesized within the past century (e.g., lysergic acid diethylamide, LSD) while others have been used in ritual practices for generations in certain cultural contexts (e.g., mescaline and psilocybin mushrooms).”
Self-citationThe phenomenology of psilocybin: transformative insights for research and clinical practice
Metastasio, A., Prevete, E., Venturini, S., Garofalo, A., Cecconello, B., Pisapia, N. D., & Corazza, O. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1455902 · Cited by 15
The Creative Brain: Myths and Truths
Abraham, A. (2024) · The MIT Press eBooks · doi:10.7551/mitpress/14313.001.0001 · Cited by 20
Weleff, J., Nunes, J. C., Costa, G. P. A., Sofuoglu, M., MacLean, R. R., & Aquino, J. P. D. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16045 · Cited by 15
“132,133 There is a suggestion that in both, at least, treatment-resistant depression and tobacco-use disorder, the subjective components and quality of the acute psychedelic experience may be important for therapeutic efficacy, 134 while there remains some preliminary data in OUD this may be the…”
Treatment-Resistant Depression
Hughes, M. E., & Levine, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00065-8 · Cited by 10
Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’
Kubala, P. (2023) · Deleuze and Guattari Studies · doi:10.3366/dlgs.2023.0531 · Cited by 9
Perceived attachment history predicts psychedelic experiences: A naturalistic study
Cherniak, A. D., Mikulincer, M., Brulin, J. G., & Granqvist, P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00330 · Cited by 9
“Previous research has not contextualized psychedelic-induced processes of change in a broader developmental framework, which is surprising given that psychedelic experiences have been viewed as transformational “ in fl ection points ” in personal narratives (Yaden & Grif fi ths, 2021).”
BackgroundGezon, L. L. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00381 · Cited by 14
“Recognizing social efficacy opens the door for decolonizing psychedelic science and including stakeholders in all aspects of research and implementation of programs (Fotiou, 2019; Earp & Yaden, 2021; Keel, 2022).”
BackgroundDahan, A., Jansen, S. C., van der Schrier, R. M., Sarton, E. Y., Dadiomov, D., van Velzen, M., Olofsen, E., & Niesters, M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00133 · Cited by 9
Considering distinct positive emotions in psychedelic science
Goldy, S. P., Hendricks, P. S., Keltner, D. J., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2394221 · Cited by 12
“…subjective effects may play a mechanistic role underlying therapeutic outcomes including decreased depression, anxiety, and substance misuse (e.g. Garcia-Romeu et al., 2014; Roseman et al., 2018; Weiss et al., 2024; Yaden & Griffiths, 2021) warranting further examinations of these relationships.”
Self-citationStroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., & Kamboj, S. K. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06685-8 · Cited by 14
“In particular, there is substantial evidence that the extent of the ‘mysticalness’ of the experience, including feelings of unity, oneness, awe, and meaningful insight, mediates positive therapeutic outcomes (Yaden and Griffiths 2020, Griffiths et al. 2008).”
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity
Olson, D. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231054 · Cited by 13
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
“The role of 5HT2AR, main substrate of hallucinogenic effects of classic psychedelics is particularly pertinent regarding their ability to produce long-lasting changes in behaviour (Olson, 2021; Yaden and Griffiths, 2021).”
Healy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia‐Romeu, A., Todman, M., Varon, J. P., & D'Andrea, W. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111361 · Cited by 11
“…effects of psychedelics are necessary for inducing the acute subjective experience but might not directly cause post-acute psychological benefits and that the subjective experience plays a critical mechanistic role in producing long-lasting therapeutic effects (Yaden and Griffiths, 2021).”
Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review
Chen, M. J. Q., Chen-Li, D. C. J., Chisamore, N., Husain, M. I., Vincenzo, J. D. D., Mansur, R. B., Phan, L., Johnson, D. E., McIntyre, R. S., & Rosenblat, J. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116532 · Cited by 11
The ABCs of psychedelics: a preclinical roadmap for drug discovery
Kwan, A. C., Mantsch, J. R., & McCorvy, J. D. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.017 · Cited by 11
“Clinical studies have found that certain aspects of the subjective experience are correlated with long-term therapeutic outcomes, for example, for psilocybin and depression or smoking cessation [49] or for LSD and anxiety [4].”
Psychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 10
“66 67 Studies have reported associations between mystical-type experiences and transdiagnostic clinical improvement in cancer related distress, 68 69 treatment resistant depression, 70 and substance dependencies.”
Self-citationPsychedelics and the Entropic Brain Beyond the Self
Eyghen, H. V. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2192078 · Cited by 12
“Others insist on the need for subjective experiences but include changes that do not immediately pertain to models of the self like positive mood and positive behaviors (Yaden & Griffiths, 2020).”
BackgroundHallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
Hornick, M. G., & Stefanski, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1221719 · Cited by 10
“Indeed, even when controlling the intensity of the drug’s effects, mystical-type subjective effects have been found in some studies to be “necessary” for the enduring beneficial efficacy of the drug (Garcia-Romeu et al., 2014; Yaden and Griffiths, 2021).”
BackgroundPsychological and physiological effects of extended DMTPreprint
Luan, L. X., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D. J., et al. (2023) · doi:10.31234/osf.io/vg4dp · Cited by 9
Cross-validation of the ego dissolution scale: implications for studying psychedelics
Lynn, S. J., McDonald, C. W., Sleight, F. G., & Mattson, R. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267611 · Cited by 11
“Not surprisingly, researchers have linked such expansive experiences with positive enduring therapeutic effects, although mystical experiences can evoke a complex mix of positive and negative emotions (Taves, 2020; Yaden and Griffiths, 2021).”
BackgroundMilshteyn, Y., & Bensimon, M. (2023) · Harm Reduction Journal · doi:10.1186/s12954-023-00908-5 · Cited by 11
“These psychoactive substances induce altered states of consciousness, including the sense of self [33].”
BackgroundInformed Consent in Psychedelic-Assisted Therapy
Bradberry, M. M., Appelbaum, P. S., & Gukasyan, N. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_559 · Cited by 8
A qualitative analysis of the psychedelic mushroom come-up and come-down
Brouwer, A., Brown, J. K., Erowid, E., Erowid, F., Thyssen, S., Raison, C. L., & Carhart-Harris, R. L. (2025) · npj Mental Health Research · doi:10.1038/s44184-024-00095-6 · Cited by 19
“Evidenceisstrongthattheacutesubjectiveeffects ofpsychedelicsplayaroleinmoderatingoutcomes 1 – 3 , while others argue, mostly based on rodent research, that conscious experience may be secondary or peripheral to the therapeutic effects of these agents 4 .”
Cyberdelics: Virtual reality hallucinations modulate cognitive-affective processes
Brizzi, G., Pupillo, C., Rastelli, C., Greco, A., Bernardelli, L., Natale, A. F. D., Pizzoli, S. F. M., Sajno, E., Frisone, F., Lernia, D. D., et al. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2499459 · Cited by 13
“For instance, Yaden and Griffiths (Yaden and Griffiths 2021) emphasise that subjective experiences are central to the acute effects of psychedelics, such as emotional breakthroughs and shifts in perception, which are thought to mediate their therapeutic impact.”
Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice
Erkizia-Santamaría, I., Martínez-Álvarez, N., Salinas-Novoa, L., Meana, J. J., & Ortega, J. E. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf035 · Cited by 9
“40,41 It is conceivable that certain 5HT2AR agonist drugs lacking psychedelic activity may still induce long-term neuroplastic and therapeutic effects, as suggested by some authors.”
Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials
Nayak, S. M., & Zahid, Z. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368367 · Cited by 8
Concomitant use of antidepressants and classic psychedelics: A scoping review
Tap, S. C., Thomas, K. L. H., Páleníček, T., Stenbæk, D. S., Oliveira-Maia, A. J., van Dalfsen, J. H., & Schoevers, R. A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368360 · Cited by 16
da Cruz, R. V. L., Costa, R. B. G. D. M., de Queiroz, G. M., Stojanovic, T., Moulin, T. C., & Leão, R. N. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03852-7 · Cited by 11
Where the Spirit Meets the Bone: Embodied Religiospiritual Cognition from an Attachment Viewpoint
Winter, A. L., & Granqvist, P. (2023) · Religions · doi:10.3390/rel14040511 · Cited by 9
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-85702-8_5 · Cited by 11
Self-citationAutonomy and autoheteronomy in psychedelically assisted psychotherapy
Davis, O. C. M. (2022) · Routledge eBooks · doi:10.4324/9781003331780-8 · Cited by 7
Exline, J. J., Schutt, W. A., Pait, K. C., & Wilt, J. A. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148062 · Cited by 8
“But there is also a compelling body of evidence suggesting that subjective effects of psychedelics are major predictors of important psychological changes (Yaden & Griffiths, 2021).”
BackgroundInfluentialPsilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Spangemacher, M., Mertens, L. J., Färber, L. V., Jungaberle, A., Jungaberle, H., & Gründer, G. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0224 · Cited by 12
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra, A., Oliva, H. N. P., Prudente, T. P., Kitaneh, R., Nunes, E. J., Fogg, C., Funaro, M. C., Weleff, J., Nia, A. B., & Angarita, G. A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05519-2 · Cited by 12
Glynos, N. G., Baker, A., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2025) · British Journal of Pain · doi:10.1177/20494637251319497 · Cited by 8
“…activation, enhanced neuroplasticity, and altered functional connectivity 2,3 and psychological mechanisms such as the acute effects of the subjective experience, 4,5 increased acceptance, 6 – 8 increased cognitive fl exibility, and enhanced feelings of connection to self, others, and nature.”
Kruger, D. J., Argyri, E. K., Mogilski, J. K., Herberholz, M., Barron, J., Aday, J. S., & Boehnke, K. F. (2025) · The Journal of Sex Research · doi:10.1080/00224499.2025.2479197 · Cited by 8
“Nonetheless, the dose-dependent effects observed, coupled with participants’ qualitative reports of long-term impacts, support the importance of the subjective effects of psychedelics in mediating long-term psychological changes (Aday et al., 2024; Yaden & Griffiths, 2020).”
Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes
Hooper, J., Gyongyosi, E., Hutchison, K. E., & Mueller, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1533055 · Cited by 9
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
Biased Signaling in Psychedelic Action
Wacker, D., & McCorvy, J. D. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-012545 · Cited by 10
Hewitt, T., Amaya, I. A., Beauté, R., Seth, A. K., Schmidt, T. T., & Schwartzman, D. J. (2025) · Neuroscience of Consciousness · doi:10.1093/nc/niaf020 · Cited by 13
García‐Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118720 · Cited by 8
Trauma and Remembering: From Neuronal Circuits to Molecules
Kéri, S. (2022) · Life · doi:10.3390/life12111707 · Cited by 9
“Patients receiving psychedelic-associated therapy often report heightened openness, increased trust toward the therapist, less fear and internal avoidance, and a better ability to extinct, reframe and integrate traumatic memories [96].”
BackgroundPsychedelics in the Treatment of Substance Use Disorders
Barnett, B. S., & Weleff, J. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220804-01 · Cited by 7
The zebrafish for preclinical psilocybin research
Syed, O. A., Tsang, B., & Gerlai, R. T. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105381 · Cited by 9
Editorial: The psychotherapeutic framing of psychedelic drug administration
Beckman, M., Poulsen, S., Doss, M. K., & Stenbæk, D. S. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1121234 · Cited by 7
“This is particularly important since both the therapeutic relationship and subjective aspects of the psychedelic experience are hypothesized as mechanisms of treatment effects (Kaelen et al., 2018; Murphy et al., 2021; Yaden and Griffiths, 2021).”
BackgroundFerreira, A. E., & Reis-Pina, P. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.112020 · Cited by 6
Brudner, R. M., Kaczmarek, E. S., Blainey, M. G., Schulz-Quach, C., Meshkat, S., Doyle, Z., Lipsitz, O., Offman, H., Sethi, R., Weiglein, G., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346697 · Cited by 11
“…that the subjective psychedelic experience may not be necessary for psilocybin’s antidepressant effects (Hesselgrave et al., 2021); however, others have argued that these subjective experiences are indeed necessary for psilocybin’s therapeutic benefit in humans (Yaden and Griffiths, 2021).”
Calnan, M., Blest‐Hopley, G., Busch, C., Adams, M., Ruffell, S., Piper, T., Roseman, L., Kettner, H., & Carhart-Harris, R. L. (2025) · Brain and Behavior · doi:10.1002/brb3.70660 · Cited by 10
Drewko, A. J., Habets, R. L. P., & Brunt, T. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03169-9 · Cited by 16
“…behind depression [18 – 20], as well as the fi nding that commercially available antidepressants also display some psychoplasto-genic properties [21, 22], there is a great divide over whether the hallucinogenic properties of psychedelics are useful for their therapeutic applications [23, 24].”
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults
Ermakova, A. O., Dunbar, F., Seynaeve, M., & Millière, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-22620-z · Cited by 8
Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations
Palmisano, V. F., Agnorelli, C., Fagiolini, A. M., Erritzøe, D., Nutt, D., Faraji, S., & Nogueira, J. J. (2024) · Biochemistry · doi:10.1021/acs.biochem.3c00598 · Cited by 10
Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder
Ehrenkranz, R. C., Agrawal, M., Penberthy, J. K., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357668 · Cited by 6
“This is because psychedelic experiences are often reported to increase acceptance and social connectedness, which may help shift attention away from thoughts of the deceased and counter the loneliness described by those with PGD (Prigerson & Maciejewski, 2022; Yaden & Griffiths, 2021).”
Self-citationImmersive exposure to simulated visual hallucinations modulates high-level human cognition
Greco, A., Rastelli, C., Ubaldi, A., & Riva, G. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103808 · Cited by 9
Falcon, J. (2025) · Anthropology of Consciousness · doi:10.1111/anoc.70002 · Cited by 8
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021012 · Cited by 11
Artificial intelligence and psychedelic medicine
Sarris, J. J., Halman, A., Urokohara, A., Lehrner, M., & Perkins, D. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15229 · Cited by 11
Leveraging meditation research for the study of psychedelic-related adverse effects
Palitsky, R., Canby, N. K., Dam, N. T. V., Levin-Aspenson, H. F., Kaplan, D. M., Maples‐Keller, J. L., Raison, C. L., Grant, G. H., Dunlop, B. W., & Britton, W. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2420745 · Cited by 8
“…AE cat egories identified by Lindahl et al. (2017), including shared phenomenology, common plausible mecha nisms, and similarity in the social reception of psy chedelics and meditation by subsets of the population (Holas & Kamińska, 2023; Preller & Vollenweider, 2018; Yaden & Griffiths, 2021).”
Apud, I., Scuro, J., Carrera, I., & Oliveri, A. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00202 · Cited by 7
Myers, M. G., & Toal, C. B. (1995) · PubMed · Cited by 7
Geller, J. A., & Whitney, E. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01577-2 · Cited by 6
“Changes in conscious experience seen with psychedelics include profound shifts in perception, affect, and mood through serotonin receptor agonism, which may be essential components of its therapeutic properties [47].”
Petrovitch, D., Spinks, J., Yoo, H. B., Kerr, L., Willms, J. O., Jurek, M. K., Wanzor-Box, R., Littlefield, A. K., & McCauley, B. (2025) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2025.100259 · Cited by 6
Religious and spiritual experiences from a neuroscientific and complex systems perspective
Jedlička, P., & Havenith, M. N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106319 · Cited by 16
“…functional connectivity between the anterior hippocampus and the DMN for weeks (Siegel et al., 2024) There is currently a debate between reductionist and non-reductionist interpretations of the effects of psychedelics (Barksdale et al., 2024; Gründer et al., 2024; Yaden & Griffiths, 2021) .”
Kartar, A. A., Horinouchi, T., Örzsik, B., Anderson, B., Hall, L., Bailey, D., Samuel, S., Beltran, N., Bouyagoub, S., Racey, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329411 · Cited by 12
“The induction of ASCs is suggested to be critical to the therapeutic action of psyche-delic substances [8–10], for which HVB might therefore offer a non-pharmacological alternative, with fewer legal and ethical restrictions to large-scale adoption in clinical treatment.”
d’Andrea, G., Chiappini, S., Ciavoni, L., Tucci, R., Martino, F., Semeraro, F. M., Battista, D. D., Mosca, A., Miuli, A., Carlo, F. D., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03654-3 · Cited by 10
“Such experiences, known as “ Mystical Experiences ” (CME), are hypothesized to be instrumental in producing long-lasting positive effects of psychedelics [96].”
Ascone, F., Buzzelli, V., Mottarlini, F., Trapano, M. D., Miglioranza, P., Rava, A., Feo, A., Spano, F., Hausman, M., Sugaya, K., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02361-x · Cited by 7
“Finally, although some authors argue that subjective psyche-delic experiences may be necessary for therapeutic outcomes [57], growing evidence of 5HT2AR-independent antidepressant responses in the absence of hallucinogenic effects, together with our fi ndings, support the possibility that psilocybin…”
Clarifying the ethical landscape of psychedelic-assisted psychotherapy
Kochevar, C. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2372038 · Cited by 8
“…effects of psychedelics [such as the ‘mystical’ experiences that Jacobs associates with transformativity] are necessary for their enduring beneficial effects” and “these subjective effects account for the majority of their benefit” (Yaden & Griffiths, 2021; see also Yaden, Potash et al., 2022).”
Learning how to make use of dissociative therapies
Mathai, D. S. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2406329 · Cited by 6
“Another perspective, informed by psychedelic research, is that the subjective experiences of hallucinogen-based therapies are central to therapeutic procedures and outcomes (Yaden & Griffiths, 2021).”
McMillan, R. M., Reynolds, J., & Fernandez, A. V. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2433522 · Cited by 6
“…for identifying relationships between experiences and therapeutic outcomes (Aday, et al., 2021; Haijen et al., 2018; Nikolaidis et al., 2023; Yaden & Griffiths, 2021), they are limited to assessing pre-defined constructs, and thus overlooking undefined experiential variations that may hold…”
Scuro, J. (2024) · Social Compass · doi:10.1177/00377686241301923 · Cited by 6
“Many clinical researchers emphasize subjective experiences as significant aspects in psychedelic therapies (Yaden and Griffiths, 2021).”
Psychedelics in Psychiatry: Oh, What A Trip!
Fonzo, G. A., Nemeroff, C. B., & Kalin, N. H. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241025 · Cited by 5
Metadata
- Authors
- Yaden, D. B., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 568-572
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033615
- OpenAlex
- W3113263685
- Cited by
- 541
- References
- 28
- Citations by year
- 2026: 81 · 2025: 125 · 2024: 105 · 2023: 98 · 2022: 92 · 2021: 36 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steven and Alexandra Cohen Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, subjective effects, treatment outcomes, altered states of consciousness, meaningful experiences, subjective experience, neurobiological mechanisms, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.